Dysfunction of the PGC-1α-mitochondria axis confers adriamycin-induced podocyte injury

Area of Science:

• Nephrology
• Mitochondrial Biology
• Molecular Medicine

Background:

• Adriamycin (ADR)-induced nephropathy models human focal segmental glomerulosclerosis.
• The mechanism of podocyte injury in ADR nephropathy is poorly understood.
• The role of the peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α-mitochondria axis in this process requires investigation.

Purpose of the Study:

• To test the hypothesis that the PGC-1α-mitochondria axis is involved in ADR-induced podocyte injury.
• To investigate the impact of ADR on PGC-1α expression and mitochondrial function in podocytes.
• To evaluate the therapeutic potential of targeting the PGC-1α-mitochondria axis.

Main Methods:

• Utilized MPC5 immortalized mouse podocytes and in vivo rat models.
• Administered Adriamycin (ADR) to induce nephropathy.
• Assessed podocyte injury markers (nephrin, podocin), apoptosis, and mitochondrial function (ROS, mtDNA copy number, membrane potential, ATP).
• Manipulated PGC-1α expression (overexpression and observed downregulation).

Main Results:

• ADR induced podocyte apoptosis, reduced nephrin and podocin expression, and impaired mitochondrial function.
• ADR treatment downregulated PGC-1α expression in podocytes.
• Overexpression of PGC-1α attenuated ADR-induced podocyte injury and mitochondrial dysfunction.
• Downregulation of PGC-1α and mitochondrial disruption were observed in rat kidneys after ADR administration.

Conclusions:

• Dysfunction of the PGC-1α-mitochondria axis is critically involved in Adriamycin (ADR)-induced podocyte injury.
• Targeting PGC-1α represents a potential therapeutic strategy for ADR nephropathy.
• This study highlights the PGC-1α-mitochondria axis as a novel target for treating focal segmental glomerulosclerosis.